Other Events ·
At the 2026 Annual Meeting of Stockholders held on June 18, 2026, Agios Pharmaceuticals, Inc. stockholders approved an…
AGIOAgios Pharmaceuticals, Inc.
At the 2026 Annual Meeting of Stockholders held on June 18, 2026, Agios Pharmaceuticals, Inc. stockholders approved an amendment to the 2023 Stock Incentive Plan to increase the number of shares available for issuance under the plan by 2,000,000 shares. Additionally, stockholders elected Class I directors Rahul Ballal, Ph.D., Brian Goff, and Cynthia Smith to three-the-year terms. Agios Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes therapeutic products for patients with metabolic and hematologic disorders.